Ethan Ahler

ORCID: 0009-0001-0113-1956

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy”.

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Nature(2024)10.1038/s41586-024-07205-6

N/A

4.2DataRank · unranked

326 citations

Bianca J. Lee, Jingjing Jiang, Aidan C.A. Tomlinson, Kyle J. Seamon, Alessia Mira +48 more

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

10.21203/rs.3.rs-3122478/v1

N/A

0.292DataRank · unranked

6 citations

Matthew Holderfield, Bianca Lee, Jingjing Jiang, Aidan Tomlinson, Kyle Seamon +44 more

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

UNC Libraries(2024)10.17615/1fr6-tv06

N/A

0DataRank · unranked

0 citations

Nicole Nasholm, Chiara Ambrogio, Anthony N. Milin, Yang Liu, Elsa Quintana +48 more

Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers

Cell chemical biology(2025)10.1016/j.chembiol.2025.07.004

N/A

0DataRank · unranked

6 citations

Yu Chi Yang, Ian Lai, Jangho Park, Lilian Yao, James W. Evans +15 more